Intelgenx Technologies Corp
TSX:IGX
Intelgenx Technologies Corp
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The company went IPO on 2008-05-23. The firm is focused on the development and manufacturing of pharmaceutical films. The firm's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The firm's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The company went IPO on 2008-05-23. The firm is focused on the development and manufacturing of pharmaceutical films. The firm's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The firm's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
